Logo image of ESLA

ESTRELLA IMMUNOPHARMA INC (ESLA) Stock Analyst Earnings Estimates

NASDAQ:ESLA - Nasdaq - US2975841048 - Common Stock - Currency: USD

0.94  +0.02 (+2.17%)

After market: 0.9495 +0.01 (+1.01%)

Full estimates are only available for subscribed users, you can see which data is available below.

Subscribed users also see more surprise data, now it is restricted to 4 quarters.

Examples of complete estimate data are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional estimates and surprises .

Yearly Revenue, EBIT, EBITDA and EPS Analyst Estimates
2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032
Revenue
YoY % growth
ESLA revenue by date.ESLA revenue by date.
N/AN/AN/AN/AN/A
402.53%
N/A
101.09%
N/A
50.64%
N/A
34.07%
EBITDA
YoY % growth
ESLA ebitda by date.ESLA ebitda by date.
N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
EBIT
YoY % growth
ESLA ebit by date.ESLA ebit by date.
-250K-1.685M
-574.16%
-11.114M
-559.45%
-7.31M
34.23%
N/A
-220.09%
N/A
-117.96%
N/A
-40.00%
N/A
63.07%
N/A
1,128.29%
N/A
138.84%
N/A
58.60%
N/A
37.29%
Operating Margin
ESLA operating margin by date.ESLA operating margin by date.
N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
EPS
YoY % growth
ESLA eps by date.ESLA eps by date.
N/AN/AN/AN/AN/AN/AN/A
-63.04%
N/A
-24.00%
N/A
66.67%
N/A
1,080.65%
N/A
128.29%
N/A
51.30%
N/A
29.14%

All data in USD

Quarterly Revenue, EBIT, EBITDA and EPS Analyst Estimates
Q4 / 25
EPS
Q2Q % growth
-0.11
Revenue
Q2Q % growth
EBITDA
Q2Q % growth
N/A
EBIT
Q2Q % growth
-5.569M
-430.30%

All data in USD

Recent Earnings VS Estimates Surprises (USD)
PeriodReportedEstimateDifferenceSurprise
Q3 2025
Q2Q % growth
-0.06 -0.110.0546.52%
ESLA Yearly EPS VS EstimatesESLA Yearly EPS VS EstimatesYearly EPS VS Estimates 2025 2026 2027 2028 2029 2030 2031 2032 0 5 10
Recent Revenue VS Estimates Surprises (USD)
PeriodReportedEstimateDifferenceSurprise
ESLA Yearly Revenue VS EstimatesESLA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2028 2029 2030 2031 2032 500M 1B 1.5B 2B
EPS and Revenue Revisions
Next Q (1 month) Next Q (3 month) Next Year (1 month) Next Year (3 month)
EPSN/A N/A 0% 0%
RevenueN/A N/A N/A N/A